Literature DB >> 1578260

Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

S Przedborski1, V Kostic, V Jackson-Lewis, A B Naini, S Simonetti, S Fahn, E Carlson, C J Epstein, J L Cadet.   

Abstract

Administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mammals causes damage to the nigrostriatal dopaminergic pathway similar to that observed in Parkinson's disease. It has been suggested that the mechanism by which MPTP kills dopamine (DA) neurons involves an energy crisis due to the inhibition of mitochondrial complex I. In addition, superoxide radicals (O2-), generated subsequent to the blockade of mitochondrial complex I, may also be involved in MPTP-induced neurotoxicity. Superoxide dismutase (SOD) is a scavenger enzyme that protects cells from the hazard of O2- radicals. To evaluate further the role of O2- radical in MPTP-induced toxicity, we tested the effects of MPTP in transgenic mice with increased SOD activity. In nontransgenic littermates with normal SOD activity, MPTP injection causes a marked reduction in striatal levels of DA and its metabolites as well as in striatal and nigral 3H-DA uptake; these findings are consistent with a loss in dopaminergic neurons. In contrast, in transgenic mice with increased SOD activity, MPTP injection does not cause any significant changes either in levels of DA and metabolites or in 3H-DA uptake. We show that this lack of toxicity is not due to a lower delivery of MPTP to the brain following its intraperitoneal injection, to reduced brain biotransformation of MPTP to N-methyl-4-phenylpyridinium ion (MPP+), to diminished striatal mitochondrial monoamine oxidase B activity, to decreased synaptosomal uptake of MPP+, to lower potency of MPP+ to inhibit the complex I of the mitochondrial electron transport chain, or to faster brain elimination of MPP+. These results suggest that increased SOD activity is, most likely, the protective factor that confers resistance to transgenic mice against MPTP-induced neurotoxicity. Thus, this study provides further evidence that some of the deleterious effects of MPTP may be mediated by O2- radicals. The similarity between the MPTP model and Parkinson's disease further raises the possibility that oxy-radicals may play a significant role in the etiology of this neurodegenerative disorder.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1578260      PMCID: PMC6575882     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  96 in total

1.  Neuroprotective effect of acute and chronic administration of copper (II) sulfate against MPP+ neurotoxicity in mice.

Authors:  M Alcaraz-Zubeldia; P Rojas; C Boll; C Rios
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

Review 2.  On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies.

Authors:  Carolina Muscoli; Salvatore Cuzzocrea; Dennis P Riley; Jay L Zweier; Christoph Thiemermann; Zhi-Qiang Wang; Daniela Salvemini
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

3.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  Du-Chu Wu; Peter Teismann; Kim Tieu; Miquel Vila; Vernice Jackson-Lewis; Harry Ischiropoulos; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

Review 4.  Oxidative stress and nitration in neurodegeneration: cause, effect, or association?

Authors:  Harry Ischiropoulos; Joseph S Beckman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

5.  An elevated level of copper zinc superoxide dismutase fails to prevent oxygen induced retinopathy in mice.

Authors:  C Klaeger; L de Sa; A J Klaeger; E J Carlson; W V Good; C J Epstein
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

6.  Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.

Authors:  Naomi Matoh; Seigo Tanaka; Masanori Takehashi; Marek Banasik; Todd Stedeford; Eliezer Masliah; Shigehiko Suzuki; Yoshihiko Nishimura; Kunihiro Ueda
Journal:  Gene Expr       Date:  2003

7.  D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.

Authors:  Kim Tieu; Celine Perier; Casper Caspersen; Peter Teismann; Du-Chu Wu; Shi-Du Yan; Ali Naini; Miquel Vila; Vernice Jackson-Lewis; Ravichandran Ramasamy; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 8.  Mutant CuZn superoxide dismutase in motor neuron disease.

Authors:  M E Gurney; R Liu; J S Althaus; E D Hall; D A Becker
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

9.  Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains.

Authors:  Jason Callio; Tim D Oury; Charleen T Chu
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

10.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.